Drug profile · INN
trimethaphan camsylate
ARFONAD
trimethaphan camsylate (ARFONAD) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — trimethaphan camsylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trimethaphan camsylate (ARFONAD) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Neuronal acetylcholine receptor; alpha3/beta4 antagonist
Primary target: Neuronal acetylcholine receptor; alpha3/beta4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is trimethaphan camsylate?
trimethaphan camsylate (ARFONAD) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for trimethaphan camsylate?
ARFONAD is a marketed brand name for trimethaphan camsylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trimethaphan camsylate?
trimethaphan camsylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.